Causes of death in men with prevalent diabetes and newly diagnosed high-versus favorable-risk prostate cancer

International Journal of Radiation Oncology Biology Physics

Volumn 77, Issue 5, 2010, Pages 1329-1337

  D'Amico, Anthony V ^a   Braccioforte, Michelle H ^b   Moran, Brian J ^b   Chen, Ming Hui ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b Prostate Cancer Foundation of Chicago   (United States)

^c UNIVERSITY OF CONNECTICUT   (United States)

Author keywords

cause of death; Diabetes; prostate cancer

Indexed keywords

CAUSE OF DEATH; CAUSES OF DEATH; CHICAGO; COMPETING RISKS; CONFIDENCE INTERVAL; COX REGRESSION ANALYSIS; DIABETES; DIABETES MELLITUS; HAZARD RATIO; PROSTATE CANCERS;

DISEASES; RADIOTHERAPY; REGRESSION ANALYSIS;

RISK ANALYSIS;

ADULT; AGED; ARTICLE; BRACHYTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE SEVERITY; EXTERNAL BEAM RADIOTHERAPY; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSTATE CANCER; RISK ASSESSMENT; CANCER STAGING; CAUSE OF DEATH; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSTATE TUMOR; REGRESSION ANALYSIS; RISK FACTOR;

AGED; AGED, 80 AND OVER; BRACHYTHERAPY; CAUSE OF DEATH; DIABETES MELLITUS; HUMANS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROSTATIC NEOPLASMS; REGRESSION ANALYSIS; RISK ASSESSMENT; RISK FACTORS;

EID: 77955504105     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2009.06.051     Document Type: Article

References (34)

1. P.C. Walsh, T.L. DeWeese, and M.A. Eisenberger Clinical practice: Localized prostate cancer N Engl J Med 357 2007 2696 2705
2. A.V. D'Amico, R. Whittington, and S.B. Malkowicz Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer JAMA 280 1998 969 974 (Pubitemid 28445094)
3. G.S. Merrick, R.W. Galbreath, and W.M. Butler Primary Gleason pattern does not impact survival after permanent interstitial brachytherapy for Gleason score 7 prostate cancer Cancer 110 2007 289 296
4. S.M. Park, M.K. Lim, and S.A. Shin Impact of prediagnosis smoking, alcohol, obesity, and insulin resistance on survival in male cancer patients: National Health Insurance Corporation study J Clin Oncol 24 2006 5017 5024
5. L.V. van de Poll-Franse, S. Houterman, and M.L. Jannssen-Heijnen Less aggressive treatment and worse overall survival in cancer patients with diabetes: A large population based analysis Int J Cancer 120 2007 1986 1992
6. M.R. Smith, K. Bae, and J.A. Efstathiou Diabetes and mortality in men with locally advanced prostate cancer: RTOG 9202 J Clin Oncol 26 2008 4333 4339
7. B.B. Barone, Y. Yeh Hsin-Chieh, and C.F. Synder Long-term all cause mortality in cancer patients with preexisting diabetes mellitus JAMA 300 2008 2754 2764
8. F.L. Greene Prostate F.L. Greene, D.L. Page, I.D. Fleming, AJCC Cancer Staging Manual 6th ed 2002 Springer New York 309 316
9. M.R. Cooperberg, J. Cowan, and J.M. Broering High-risk prostate cancer in the United States, 1990-2007 World J Urol 26 2008 211 218
10. D'Amico, AV, Moran BJ, Braccioforte MH, et al. Risk of death from prostate cancer following brachytherapy alone or with radiation, androgen suppression therapy or both in men with high-risk disease. J Clin Oncol. Electronic publication July 13, 2009.
11. N.L. Keating, A.J. O'Malley, and M.R. Smith Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer J Clin Oncol 24 2006 4448 4456
12. A. Agresti, An Introduction to Categorical Data Analysis 2nd ed 2002 John Wiley & Sons New York 16 52
13. M. Hollander, D.A. Wolfe, Nonparametric Statistical Methods 2nd ed 1999 John Wiley & Sons New York 189 269
14. A. Agresti, An Introduction to Categorical Data Analysis 2nd ed 2002 John Wiley & Sons New York 165 210
15. I.M. Thompson, D.P. Ankerst, and C. Chi Assessing prostate cancer risk: Results from the Prostate Cancer Prevention Trial J Natl Cancer Inst 98 2006 529 534 (Pubitemid 43898816)
16. J.P. Fine, and R.J. Gray A proportional hazards model for the sub distribution of a competing risk J Am Stat Assoc 94 1999 496 509
17. J.P. Klein, and M.L. Moeschberger Semiparametric proportional hazards regression with fixed covariates J.P. Klein, M.L. Moeschberger, Survival Analysis: Techniques for Censored and Truncated Data 2nd ed 2003 Springer New York 243 293
18. W.R. Lee, A.F. deGuzman, and R.L. Bare Postbrachytherapy analysis of transperineal interstitial permanent prostate brachytherapy: Evidence for a learning curve in the first year at a single institution Int J Radiat Oncol Biol Phys 46 2000 83 88
19. J.J. Gaynor, E.J. Feuer, and C.C. Tan On the use of cause-specific failure and conditional failure probabilities: Examples from clinical oncology data J Am Stat Assoc 88 1993 400 409
20. R.J. Gray A class of K-sample tests for comparing the cumulative incidence of a competing risk Ann Stat 16 1988 1141 1154
21. E.L. Kaplan, and P. Meier Non-parametric estimation from incomplete observations J Am Stat Assoc 53 1958 457 500
22. J. Neter, W. Wassermann, M. Kutner, Simultaneous inferences and other topics in regression analyses-1. In: Applied Linear Regression Models 1983 Richard D Irwin Homewood, IL 150 153
23. J. Charlton, R. Latinovic, and M.C. Gulliford Explaining the decline in early mortality in men and women with type 2 diabetes: A population-based cohort study Diabetes Care 31 2008 1761 1766
24. Available from: www.cancer.org/docroot/cri/content/cri-2-4-3x-can- prostate-cancer-be-found-early-36.asp. Accessed January 15, 2009.
25. W.J. Catalona Management of prostate cancer N Engl J Med 331 1994 996 1004
26. T. Wiegel, D. Bottke, and N. Willich Phase III results of adjuvant radiotherapy (RT) versus wait-and-see (WS) in patients with pT3 prostate cancer following radical prostatectomy (RP) (ARO 96-02/AUO AP 09/95). ASCO Annual Meeting Proceedings Part I J Clin Oncol 25 Suppl. 2007 5060
27. M. Bolla, H. van Poppel, and L. Collette European Organization for Research and Treatment of Cancer. Postoperative radiotherapy after radical prostatectomy: A randomized controlled trial (EORTC trial 22911) Lancet 366 2005 572 578
28. I.M. Thompson, C.M. Tangen, and J. Paradelo Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: Long-term follow-up of a randomized clinical trial J Urol 181 2009 956 962
29. M. Roach III, K. Bae, and J. Speight Short-term neoadjuvant androgen deprivation therapy and external bean radiotherapy for locally advanced prostate cancer; Long-term results of RTOG 8610 J Clin Oncol 26 2008 585 591
30. M.V. Pilepich, K. Winter, and C.A. Lawton Androgen suppression adjuvant to definitive radiotherapy in prostate carcinoma - Long-term results of phase III RTOG 85-31 Int J Radiat Oncol Biol Phys 61 2005 1285 1290 (Pubitemid 40470408)
31. G.E. Hanks, T.F. Pajak, and A. Porter Phase III trial of long-term adjuvant androgen deprivation after neoadjuvant hormonal cytoreduction and radiotherapy in locally advanced carcinoma of the prostate: The Radiation Therapy Oncology Group protocol 9202 J Clin Oncol 21 2003 3972 3978
32. J. Denham, A. Steigler, and D.S. Lamb Short-term androgen deprivation and radiotherapy for locally advanced prostate cancer: Results from the Tran-Tasman Radiation Oncology Group 96-01 randomised controlled trial Lancet Oncol 6 2005 841 850
33. A.V. D'Amico, M. Chen, and A.A. Renshaw Androgen suppression and radiation vs radiation alone for prostate cancer: A randomized trial JAMA 299 2008 289 295
34. S.J. Freedland, E.B. Humphreys, and L.A. Mangold Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy JAMA 294 2005 433 439